Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) CEO Seth Lederman acquired 2,000 shares of the stock in a transaction dated Thursday, August 27th. The stock was bought at an average cost of $13.79 per share, with a total value of $27,580.00. Following the completion of the purchase, the chief executive officer directly owned 11,005 shares in the company, valued at approximately $151,758.95. The trade was a 22.21% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Seth Lederman also recently made the following trade(s):
- On Tuesday, June 9th, Seth Lederman bought 5,000 shares of Tonix Pharmaceuticals stock. The stock was bought at an average price of $11.79 per share, with a total value of $58,950.00.
Tonix Pharmaceuticals Stock Performance
NASDAQ TNXP opened at $14.10 on Tuesday. The business’s 50 day moving average price is $12.02 and its 200-day moving average price is $12.96. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $9.40 and a fifty-two week high of $31.55. The company has a market cap of $241.81 million, a P/E ratio of -1.09 and a beta of 1.69.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Raymond James Financial reissued a “strong-buy” rating and issued a $27.00 price objective on shares of Tonix Pharmaceuticals in a research note on Monday, August 10th. Weiss Ratings cut Tonix Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Finally, TD Cowen upgraded Tonix Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $24.50.
View Our Latest Report on Tonix Pharmaceuticals
Institutional Investors Weigh In On Tonix Pharmaceuticals
Several large investors have recently added to or reduced their stakes in TNXP. Legal & General Group Plc bought a new position in Tonix Pharmaceuticals in the 2nd quarter worth about $25,000. State of Wyoming bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals in the third quarter valued at approximately $29,000. California State Teachers Retirement System grew its stake in Tonix Pharmaceuticals by 221.9% in the second quarter. California State Teachers Retirement System now owns 2,437 shares of the company’s stock worth $31,000 after purchasing an additional 1,680 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new position in Tonix Pharmaceuticals in the second quarter worth approximately $65,000. 82.26% of the stock is owned by hedge funds and other institutional investors.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.
Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.
Featured Stories
- Five stocks we like better than Tonix Pharmaceuticals
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
